-
Je něco špatně v tomto záznamu ?
Engineered retroviral virus-like particles for receptor targeting
I. Voráčková, P. Ulbrich, WE. Diehl, T. Ruml,
Jazyk angličtina Země Rakousko
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2002-01-01 do 2017-12-31
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2002-01-01 do 2017-12-31
Public Health Database (ProQuest)
od 2002-01-01 do 2017-12-31
- MeSH
- antigeny povrchové metabolismus MeSH
- buněčné linie MeSH
- glutamátkarboxypeptidasa II metabolismus MeSH
- lidé MeSH
- makromolekulární látky metabolismus MeSH
- malá interferující RNA metabolismus MeSH
- Masonův-Pfizerův opičí virus genetika MeSH
- přichycení viru * MeSH
- transdukce genetická * MeSH
- virům podobné částice genetika metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Retroviral gag proteins, as well as fragments minimally containing the capsid (CA) and nucleocapsid (NC) subunits of Gag, are able to spontaneously assemble into virus-like particles (VLPs). This occurs in mammalian and bacterial cells as well as in in vitro systems. In every circumstance, nucleic acids are incorporated into the forming particles. Here, we took advantage of an in vitro system for the generation of non-enveloped Mason-Pfizer monkey virus (M-PMV) VLPs derived from a self-assembling CA-NC subunit of Gag. These VLPs were modified through N-terminal extension of CA-NC with short oligopeptides that, after the assembly process, were exposed on the surface of VLPs. The employed N-terminal modifications allowed specific interaction with target cells expressing prostate-specific membrane antigen. Using this system, we were able to incorporate selected siRNA into forming VLPs and deliver it into the cytosol of target cells. In comparison with other viral vectors designed for targeted transgene delivery, this M-PMV VLP system represents the lowest risk of generating virus-associated pathology, as the VLPs do not contain any viral coding sequences and are formed in a cell-free system.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14074590
- 003
- CZ-PrNML
- 005
- 20141007103941.0
- 007
- ta
- 008
- 141006s2014 au f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00705-013-1873-6 $2 doi
- 035 __
- $a (PubMed)24132720
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a au
- 100 1_
- $a Voráčková, Irena $u Department of Biochemistry and Microbiology, Institute of Chemical Technology Prague, Technicka 5, 166 28, Prague 6, Czech Republic.
- 245 10
- $a Engineered retroviral virus-like particles for receptor targeting / $c I. Voráčková, P. Ulbrich, WE. Diehl, T. Ruml,
- 520 9_
- $a Retroviral gag proteins, as well as fragments minimally containing the capsid (CA) and nucleocapsid (NC) subunits of Gag, are able to spontaneously assemble into virus-like particles (VLPs). This occurs in mammalian and bacterial cells as well as in in vitro systems. In every circumstance, nucleic acids are incorporated into the forming particles. Here, we took advantage of an in vitro system for the generation of non-enveloped Mason-Pfizer monkey virus (M-PMV) VLPs derived from a self-assembling CA-NC subunit of Gag. These VLPs were modified through N-terminal extension of CA-NC with short oligopeptides that, after the assembly process, were exposed on the surface of VLPs. The employed N-terminal modifications allowed specific interaction with target cells expressing prostate-specific membrane antigen. Using this system, we were able to incorporate selected siRNA into forming VLPs and deliver it into the cytosol of target cells. In comparison with other viral vectors designed for targeted transgene delivery, this M-PMV VLP system represents the lowest risk of generating virus-associated pathology, as the VLPs do not contain any viral coding sequences and are formed in a cell-free system.
- 650 _2
- $a antigeny povrchové $x metabolismus $7 D000954
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a glutamátkarboxypeptidasa II $x metabolismus $7 D043425
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a makromolekulární látky $x metabolismus $7 D046911
- 650 _2
- $a Masonův-Pfizerův opičí virus $x genetika $7 D016093
- 650 _2
- $a malá interferující RNA $x metabolismus $7 D034741
- 650 12
- $a transdukce genetická $7 D014161
- 650 _2
- $a virům podobné částice $x genetika $x metabolismus $7 D022701
- 650 12
- $a přichycení viru $7 D053585
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ulbrich, Pavel
- 700 1_
- $a Diehl, William E
- 700 1_
- $a Ruml, Tomáš
- 773 0_
- $w MED00009266 $t Archives of virology $x 1432-8798 $g Roč. 159, č. 4 (2014), s. 677-88
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24132720 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20141006 $b ABA008
- 991 __
- $a 20141007104418 $b ABA008
- 999 __
- $a ok $b bmc $g 1042473 $s 873502
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 159 $c 4 $d 677-88 $i 1432-8798 $m Archives of virology $n Arch Virol $x MED00009266
- LZP __
- $a Pubmed-20141006